BioClin clears $30m in series B funding

Mar 23, 2017 • Robert Lavine

Novo-backed BioClin Therapeutics will put the funding toward advancing an antibody it is developing as a metastatic bladder cancer treatment through phase 1b/2 trials.

BioClin Therapeutics, a US-based monoclonal antibody developer backed by pharmaceutical firm Novo, completed a $30m series B round co-led by venture capital firms Sofinnova Ventures and Ysios Capital yesterday.

VC firm HealthCap, investment firm Life Sciences Partners (LSP) and investment adviser Tekla Capital Management also participated in the round, which BioClin said increased its overall funding to $59m.

Founded in 2010, BioClin is working on a monoclonal antibody that will form the basis for therapies to be used in areas…

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.

Find out more

FUNDING ROUND DATA

Which corporates are backing which startups? Search our corporate deal database.

CVC DIRECTORY

Find details about global CVC units in the CVC Directory

SPECIAL REPORT

Finding a new path: How venture units guide corporations through transformational change

Events

Webinar: Designing a winning CVC platform – Engagement, venture development, operations

Jan 15, 2025
Online

Find out more All events

Events

GCV Institute: CVC Investment Programs

Jan 28 -
Jan 29, 2025
Online

Find out more All events

Events

GCV Institute: CVC Investment Programs

Mar 17 -
Mar 18, 2025
Palo Alto, CA (USA)

Find out more All events

Events

GCVI Summit 2025

Mar 18 -
Mar 20, 2025
Monterey, CA (USA)

Find out more All events

Events

GCV Institute: Landing the Value of Corporate Venturing

May 1 -
May 6, 2025
Online

Find out more All events

Events

GCV Symposium 2025

Jun 17 -
Jun 19, 2025
London (UK)

Find out more All events

About us

GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.